NCT04600141 (HEPMAB) is a Phase 3 clinical trial of Tocilizumab in Covid19, sponsored by University of Sao Paulo.

Who is sponsoring NCT04600141?

NCT04600141 is sponsored by University of Sao Paulo.

What drugs are being tested in NCT04600141?

Interventions in NCT04600141: Tocilizumab, Heparin - Therapeutic dosage, Heparin - Prophylactic dosage.

Is NCT04600141 still recruiting?

NCT04600141 is currently completed. Last updated 18 March 2022.

Last reviewed 2022-03-18 · How we verify

NCT04600141: HEPMAB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection

Completed Phase 3 Last updated 18 March 2022

What this trial tests

Phase 3 trial testing Tocilizumab in Covid19 in 308 participants. Completed in 31 December 2021.

Timeline

10 November 2020

Primary endpoint
20 October 2021

31 December 2021

Quick facts

Lead sponsor	University of Sao Paulo
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	308
Start date	10 November 2020
Primary completion	20 October 2021
Estimated completion	31 December 2021
Sites	3 locations across Brazil

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →
Heparin - Therapeutic dosage — full drug profile →
Heparin - Prophylactic dosage — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

University of Sao Paulo

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The COVID-19 infection primarily manifests itself as a respiratory tract infection, although new evidence indicates that this disease has systemic involvement involving multiple systems including the cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immune systems. Recent studies have shown that in its pathophysiology, inflammation and thrombogenesis predominate, especially in the severe forms of COVID-19. Thus, the investigators hypothesized that the use of heparin and tocilizumab could potencially reduce inflammation and thrombogenesis in patients with severe COVID-19 infection, improving patients outcomes and survival.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Zizzo G, Tamburello A, Castelnovo L, Laria A, et al · · 2022 · cited 55× · PMID 35340805 · DOI 10.3389/fimmu.2022.795315
Anticoagulants for people hospitalised with COVID-19: a rapid review
Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, et al · · 2022 · cited 41× · PMID 35244208 · DOI 10.1002/14651858.cd013739.pub2
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact.
Zhang S, Asquith B, Szydlo R, Tregoning JS, et al · · 2021 · cited 31× · PMID 35965490 · DOI 10.1093/immadv/ltab015
COVID-19 and venous thromboembolism: A narrative review.
Angelini DE, Kaatz S, Rosovsky RP, Zon RL, et al · · 2022 · cited 24× · PMID 35224417 · DOI 10.1002/rth2.12666
Mast cells: Therapeutic targets for COVID-19 and beyond.
Lam HY, Tergaonkar V, Kumar AP, Ahn KS. · · 2021 · cited 17× · PMID 34467628 · DOI 10.1002/iub.2552
D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients.
Thoreau B, Galland J, Delrue M, Neuwirth M, et al · · 2021 · cited 16× · PMID 33926038 · DOI 10.3390/v13050758

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other University of Sao Paulo trials

Trials by the same sponsor.

NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07522554 — Lavender and Lemongrass Aromatherapy for Pain and Anxiety in Labor: A Randomized Trial · NA · active not recruiting
NCT07479940 — Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters · NA · active not recruiting
NCT07445178 — Piecemeal Resection and Advanced Histology Independently Predict Local Recurrence After Colorectal Snare-based Endoscopi · completed
NCT07170007 — Physiotherapeutic Protocol Compared to Usual Care in the Treatment of Primiparas After Perineal Trauma · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04600141 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo
Last refreshed: 18 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04600141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing